David Lebowitz

Stock Analyst at Citigroup

(3.94)
# 622
Out of 5,008 analysts
119
Total ratings
59.77%
Success rate
8.42%
Average return

Stocks Rated by David Lebowitz

Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69$84
Current: $69.03
Upside: +21.69%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77$84
Current: $60.64
Upside: +38.52%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56$48
Current: $26.37
Upside: +82.03%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35$20
Current: $21.29
Upside: -6.06%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243$290
Current: $210.83
Upside: +37.55%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88$103
Current: $87.23
Upside: +18.08%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31$38
Current: $32.28
Upside: +17.72%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15$22
Current: $15.90
Upside: +38.36%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58$67
Current: $54.61
Upside: +22.69%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45$56
Current: $39.99
Upside: +40.04%
Maintains: Neutral
Price Target: $14$10
Current: $20.54
Upside: -51.31%
Maintains: Neutral
Price Target: $4$1.5
Current: $1.48
Upside: +1.35%
Maintains: Sell
Price Target: $32$45
Current: $64.81
Upside: -30.57%
Maintains: Buy
Price Target: $65$68
Current: $72.45
Upside: -6.14%
Initiates: Buy
Price Target: $382
Current: $442.31
Upside: -13.64%
Maintains: Neutral
Price Target: $103$96
Current: $55.61
Upside: +72.63%
Maintains: Equal-Weight
Price Target: $18$12
Current: $6.28
Upside: +91.08%
Maintains: Equal-Weight
Price Target: $170$164
Current: $452.00
Upside: -63.72%
Maintains: Overweight
Price Target: $36$39
Current: $19.76
Upside: +97.37%
Maintains: Equal-Weight
Price Target: $20$21
Current: $16.41
Upside: +27.97%
Maintains: Overweight
Price Target: $435$405
Current: $6.16
Upside: +6,474.68%
Maintains: Equal-Weight
Price Target: $13$14
Current: $1.48
Upside: +845.95%